MedTrace Logo

Evaluation of New Biomarkers of Thrombosis in Myeloproliferative Neoplasms

NCT04177576 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 397

Last updated 2022-10-06

No results posted yet for this study

Summary

Thrombosis is the main cause of morbidity and mortality in patients with myeloproliferative neoplasms (MPN). However, the pathogenesis of thrombosis in MPN is still largely elusive. Neutrophils can release their decondensed chromatin as a network of extracellular fibers named NET for "neutrophils extracellular trap". NETs are known to be procoagulant. Our main objective is to quantify NETs biomarkers expression in MPN patients and define if they could be used as prognostic factors in the outcome of thrombosis in these patients.

Conditions

  • Myeloproliferative Neoplasm

Interventions

BIOLOGICAL

2 additional tubes of blood

2 additional tubes of blood will be collected to prepare plasma aliquots used tomeasure markers of neutrophil activation

Sponsors & Collaborators

  • University Hospital, Bordeaux

    lead OTHER

Principal Investigators

  • Chloé JAMES · University Hospital, Bordeaux

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-24
Primary Completion
2022-01-26
Completion
2022-01-26

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04177576 on ClinicalTrials.gov